Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pona-CELL: Ponatinib + Reduced-Intensity Chemo in Ph+ ALL
NCT04554459Phase 2Terminated
- Sponsor
- Institute of Hematology and Blood Transfusion
- Start
- Feb 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ponatinib in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Transfusion. Started Feb 2021; status: terminated.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04554459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554459.